(Rac)-Zevaquenabant
Product Specifications
UNSPSC Description
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis[1].
Target Antigen
Cannabinoid Receptor; NO Synthase
Type
Reference compound
Related Pathways
GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/rac-zevaquenabant.html
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=S(/N=C(N1N=C(C2=CC=C(Cl)C=C2)C(C3=CC=CC=C3)C1)/N=C(N)/C)(C4=CC=C(C(F)(F)F)C=C4)=O
Molecular Weight
547.98
References & Citations
[1]Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB 1 R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-141411/Rac-Zevaquenabant-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-141411/Rac-Zevaquenabant-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1610420-28-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
